Radius jumps on Phase III osteoporosis data

Radius Health Inc. (NASDAQ:RDUS) gained $5.42 (17%) to $37.45 after abaloparatide-SC met the primary endpoint of a Phase III study to reduce fractures in postmenopausal osteoporosis.

In the ACTIVE trial, abaloparatide-SC reduced the rate of incident vertebral fracture after 18 months by 83% compared to placebo (0.72% vs 4.36%, p<0.0001). Patients in a third arm of the study received Forteo teriparatide from Eli Lilly and Co. (NYSE:LLY); the fracture rate in this group was 78% less than placebo (0.98%, p<0.0001). ...